Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer’s Healthcare Insight (136)
September 12, 2011
- Maurer's Healthcare Insight (135)
August 15, 2011
- Maurer's Healthcare Insight (134)
August 1, 2011
- Maurer's Healthcare Insight (133)
July 11, 2011
- Maurer's Healthcare Insight (132)
May 30, 2011
- Maurer's Healthcare Insight (131)
April 18, 2011
- Maurer's Healthcare Insight (130)
January 24, 2011
- Maurer's Healthcare Insight (129)
January 3, 2011
- Maurer's Healthcare Insight (128)
December 13, 2010
- Maurer's Healthcare Insight (127)
November 29, 2010
- Maurer's Healthcare Insight (126)
November 8, 2010
- Maurer's Healthcare Insight (125)
October 25, 2010
- Maurer's Healthcare Insight (124)
October 11, 2010
- Maurer's Healthcare Insight (123)
July 12, 2010
- Maurer's Healthcare Insight (122)
May 31, 2010
- Maurer's Healthcare Insight (121)
May 3, 2010
- Maurer's Healthcare Insight (120)
April 12, 2010
- Maurer's Healthcare Insight (119)
March 1, 2010
- Maurer's Healthcare Insight (118)
January 4, 2010
- Maurer's Healthcare Insight (117)
December 14, 2009
ページ
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…